NAS:FGEN (USA)
Business Description
FibroGen Inc
NAICS : 325412
SIC : 2834
409 Illinois Street, San Francisco, CA, USA, 94158
Compare
Compare
Traded in other countries / regions
1FG.Germany
•
FGEN.Mexico
•
0IL8.UK
•
FGEN.USA
Description
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.66 | |||||
| Equity-to-Asset | 0.15 | |||||
| Debt-to-Equity | 0.91 | |||||
| Debt-to-EBITDA | -0.45 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -1.59 | |||||
| Beneish M-Score | -3.46 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 0.2 | |||||
| 3-Year EBITDA Growth Rate | -53.7 | |||||
| 3-Year EPS without NRI Growth Rate | -45 | |||||
| 3-Year FCF Growth Rate | -6.7 | |||||
| 3-Year Book Growth Rate | -27.7 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 4.94 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 66.37 | |||||
| 9-Day RSI | 66.6 | |||||
| 14-Day RSI | 65.51 | |||||
| 6-1 Month Momentum % | -22.85 | |||||
| 12-1 Month Momentum % | -3.97 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.17 | |||||
| Quick Ratio | 2 | |||||
| Cash Ratio | 1.82 | |||||
| Days Inventory | 706.75 | |||||
| Days Sales Outstanding | 43.03 | |||||
| Days Payable | 689.33 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.8 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 93.37 | |||||
| Operating Margin % | -85.69 | |||||
| Net Margin % | -83.64 | |||||
| ROE % | -104.09 | |||||
| ROA % | -28.47 | |||||
| ROIC % | -80.73 | |||||
| ROC (Joel Greenblatt) % | -184.59 | |||||
| ROCE % | -40.76 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 5.12 | |||||
| PB Ratio | 13.09 | |||||
| Price-to-Tangible-Book | 13.05 | |||||
| EV-to-EBIT | -4.6 | |||||
| EV-to-EBITDA | -4.83 | |||||
| EV-to-Revenue | 3.85 | |||||
| EV-to-FCF | -8.61 | |||||
| Earnings Yield (Greenblatt) % | -21.74 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:FGEN
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 263.149 | ||
| EPS (TTM) ($) | -2.37 | ||
| Beta | 0.47 | ||
| Volatility % | 45.79 | ||
| 14-Day RSI | 65.51 | ||
| 14-Day ATR ($) | 0.750667 | ||
| 20-Day SMA ($) | 13.108 | ||
| 12-1 Month Momentum % | -3.97 | ||
| 52-Week Range ($) | 7.81 - 16.91 | ||
| Shares Outstanding (Mil) | 93.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
FibroGen Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||